Mary Mulready Sullivan Oncology Symposium: Hepatocellular Carcinoma: A Multifaceted Comprehensive Approach

Wednesday, May 12, 2021, 12:30 PM - 4:45 PM, ZOOM, Hartford, CT


AMA PRA Category 1 Credits™ (2.50 hours), AMA PRA Category 1 Credits™ (1.50 hours), Non-Physician Attendance (credits designated as AMA PRA Category 1) (1.50 hours), Non-Physician Attendance (credits designated as AMA PRA Category 1) (2.50 hours), ANCC Contact Hour(s) (2.50 hours), ANCC Contact Hour(s) (1.50 hours), Oncology Education (1.50 hours), Oncology Education (2.50 hours)

In 2021, an estimated 42,230 new cases of primary liver cancer (including intrahepatic bile duct cancers) will be diagnosed in the US and 30,230 people will die from the disease. Approximately three fourths of liver cancers are hepatocellular carcinoma (HCC). Liver cancer incidence is 3 times higher in men than in women (American Cancer Society Facts and Figures 2021). Incidence trends: Liver cancer incidence has more than tripled since 1980; the rate continued to increase by more than 2% per year in women from 2013 to 2017 but has stabilized in men. Hepatocellular carcinoma (HCC) is the fifth most common cancer in men, worldwide, and seventh among women, with over half a million new cases diagnosed annually worldwide. It is the second leading cause of cancer related mortality in the world. Chronic liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV) accounts for the majority of HCC cases and thus, highly amenable to preventive measures. The distribution of HCC varies according to geographic location. The disease burden is highest in areas with endemic HBV infection (where HBsAg prevalence is 8% or more), such as in sub-Saharan Africa and Eastern Asia, with incidence rates of over 20 per 100,000 individuals. Mediterranean countries such as Italy, Spain, and Greece have intermediate incidence rates of 10-20 per 100,000 individuals, while North and South America have a relatively low incidence (< 5 per 100,000 individuals). Risk factors: Approximately 70% of liver cancer cases in the US could potentially be prevented through the elimination of risk factors, the most important being excess body weight, type 2 diabetes, chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), heavy alcohol consumption (3 or more drinks per day), and tobacco smoking. These can contribute to cirrhosis. Prevention: A vaccine that protects against HBV infection has been available since 1982. There is no vaccine available to prevent HCV infection, although new combination antiviral therapies can often clear established infections and likely reduce cancer risk. Early detection: Although screening for liver cancer has not been shown to reduce mortality, many health care providers in the US test individuals at high risk (e.g., those with cirrhosis) with imaging such as ultrasound and/or blood tests. Treatment: Early-stage liver cancer can sometimes be treated successfully with liver transplantation or surgery to remove part of the liver. Other treatments include tumor ablation (destruction), embolization (blocking blood flow), or radiation therapy. Patients diagnosed at an advanced stage may be offered targeted therapies or immunotherapy. Survival: The 5-year relative survival rate is 20%, up from 3% four decades ago. Even for the 44% of patients diagnosed with localized-stage disease, 5-year survival is only 34%. The 2021 Mary Mulready Sullivan Oncology Symposium will provide comprehensive information from internationally recognized experts on innovations in this important field.

1. define the demographic trends of Hepatocellular Carcinoma (HCC)
2. discuss the evidence based interventions for treatment of HCC based on disease extent.
3. articulate the surgical and medical oncology best practice interventions for hHCC
4. describe the local and systemic treatments and supportive care interventions for the patient with HCC that contribute to increased quality and quantity of life.

To register, please CLICK HERE

 

 

This activity was planned by and for the healthcare team, and learners will receive 4.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Hartford HealthCare designates this activity for a maximum of 4.00 AMA PRA Category 1 Credit(s)^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Accessibility Statement
 
Hartford HealthCare is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact continuinged@hhchealth.org.

The Hartford HealthCare Healthcare Continuing Education team adheres to Joint Accreditation for Interprofessional Continuing Education Criteria, Standards, and Policies regarding industry support of continuing medical education.  Disclosure of faculty and their commercial relationships will be made prior to the activity.

Wednesday, May 12, 2021